EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

Extrawell Pharmaceutical Holdings Limited

858 BMG3285Q1134

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 09:08:09 16/07/2024 BST			5-day change	1st Jan Change
0.041 ^HKD	0.00%		+5.13%	+20.59%

06-28	Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
06-25	Extrawell Pharmaceutical Warns of Swing to Loss in Fiscal Year 2024	MT

Extrawell Pharmaceutical Holdings Limited Appoints of Lu Zhiqiang as an Executive Director

January 27, 2017 at 06:33 am

The board of directors of Extrawell Pharmaceutical Holdings Limited announced the appointment of Mr. Lu Zhiqiang as an executive Director with effect from 27 January 2017.

Latest news about Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended March 31, 2024	06-28	CI
Extrawell Pharmaceutical Warns of Swing to Loss in Fiscal Year 2024	06-25	MT
Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2024	06-21	CI
Extrawell Pharmaceutical Holdings Limited Announces Board and Committee Changes	06-07	CI
Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses	11-30	MT
Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023	11-29	CI
Extrawell Pharmaceutical Holdings Forecasts Swing to Loss in Fiscal H1; Shares Fall 3%	11-13	MT
Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 September 2023	11-10	CI
Extrawell Pharmaceutical Amends Terms of Convertible Bonds by Innovative Pharmaceutical Biotech	12/07/23	MT
Extrawell Pharmaceutical's Fiscal Year 2023 Attributable Profit Falls	30/06/23	MT
Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/06/23	CI
Extrawell Pharmaceutical Unit Completes Share Buyback Deal	20/06/23	MT
Extrawell Pharmaceutical to Swing to Loss in FY23	16/06/23	MT
Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023	16/06/23	CI
Extrawell Pharmaceutical Holdings Limited Appoints Guo Yi as an INED of the Company, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee of the Board with Effect from 14 April 2023	14/04/23	CI
Extrawell Pharmaceutical Holdings Limited Announces Demise of Mr. Xue Jing Lun, Independent Non-Executive Director, and A Member of Each of the Audit Committee, Remuneration Committee and Nomination Committee	07/12/22	CI
Extrawell Pharmaceutical's Profit for Six Months Through September Nearly Halves	30/11/22	MT
Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2022	29/11/22	CI
Extrawell Pharmaceutical Forecasts Decline in Fiscal H1 Profit	17/11/22	MT
Extrawell Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 September 2022	17/11/22	CI
Extrawell Pharmaceutical Holdings Limited Announces Management Changes	30/09/22	CI
Extrawell Pharmaceutical Holdings Swings to Profitability in FY22	01/07/22	MT
Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended March 31, 2022	29/06/22	CI
Extrawell Pharma Sees Profit Surge in FY22	20/06/22	MT
Extrawell Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended March 31, 2022	17/06/22	CI

Chart Extrawell Pharmaceutical Holdings Limited

Duration

Period

Chart Extrawell Pharmaceutical Holdings Limited

More charts

Extrawell Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Manufacturing segment is engaged in the development, manufacture and sales of pharmaceutical products. Its self-produced products include Transfer Factor Oral Solution, Wisk, ZhouBang and others. The Trading segment is engaged in the promotion and distribution of imported pharmaceuticals. Its imported products include Millibar and Skin Cap. The Gene Development segment is engaged in the commercial development and research, development of gene-related technologies.

Sector

Pharmaceuticals

Calendar

26/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED	+20.59%	12.55M
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+38.95%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals